Clinical Trials Browser

Phase 2 × Endometrial Adenocarcinoma × MK 2206 × Clear all

NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Phase 2 Completed

37 enrolled 9 charts

Endometrial Adenocarcinoma